STAAR Surgical Company (STAA) is a medical supply company specializing in ophthalmologic equipment. The company has been operating for 25 years and specializing in implantable lenses for the use in cataract surgery “IOL” and implantable lenses used for refractive surgery “ICL.” Starr has manufacturing plants in California (2 plants), Switzerland and Japan and markets in over 50 countries.
This year the company has developed four new products that have already received regulatory approval. These should improve company cash flows. In addition, the net income was $862,000 this year which is a major improvement over last year’s $1.6 million loss. The company is improving in financial performance.
The company is also improving in stock performance. Staar’s stock remained stable around $5-$6 for a year. Then in August the stock started to rise until it reached $8 per share. No doubt that part of this was due to improved earnings and also to new products that the company has developed. These news items indicate that the stock should rise. However, the news may have also caused a buying spree as seen by much greater activity than before the news came out. In this case investors may have bought for a short term gain and when the stock levels out they will sell and the stock will go down for short term. As with all stocks, I would investigate this stock very carefully before buying it.
Some of the mangers in charge of Staar are: Hans M. Blickensdoerfer, President, Europe, Latin America, the Middle East and Africa ; Paul Hambrick, V.P. of Global Operations; Phillippe Subrin, VP of Switzerland Operations; and Craig Felberg, V.P. of Global Research and Development.
Sorry, comments are closed for this post.